申请人:Pfizer Inc.
公开号:US04281004A1
公开(公告)日:1981-07-28
A series of phenylguanidine base compounds and their pharmaceutically acceptable acid addition salts have been found to be active as oral hypoglycemic agents. Preferred member compounds include N,N'-diphenyl-1-pyrrolidinocarboxamidine, N-phenyl-N'-methyl-N'-phenyl-1-pyrrolidinocarboxamidine and N-phenyl-N'-(p-chlorophenyl)-1-pyrrolidinocarboxamidine, and their hydrohalide acid addition salts. Synthetic routes leading to these compounds are described.
一系列苯基胍基化合物及其药学上可接受的酸盐被发现作为口服降血糖药物具有活性。首选的成员化合物包括N,N'-二苯基-1-吡咯烷基甲酰胺,N-苯基-N'-甲基-N'-苯基-1-吡咯烷基甲酰胺和N-苯基-N'-(对氯苯基)-1-吡咯烷基甲酰胺及其氢卤酸盐。描述了导致这些化合物的合成路线。